Evidence map›Paper›PMID 41087622›Full record

ArticleScientific reports2025

Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy.

Richard A Erali, Steven D Forsythe, Cecilia R Schaaf, Nicholas Edenhoffer, William Meeker, Cristian D Valenzuela, Wencheng Li, Shay Soker, Reese W Randle, Konstantinos I Votanopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Richard A EraliWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
Steven D ForsytheWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
Cecilia R SchaafWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
Nicholas EdenhofferWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
William MeekerWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
Cristian D ValenzuelaWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
Wencheng LiDepartment of Pathology, Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA.
Shay SokerWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA.
Reese W RandleDivision of Surgical Oncology, Department of Surgery, Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA.
Konstantinos I VotanopoulosWake Forest Organoid Research Center, Wake Forest University, Winston-Salem, NC, USA. kvotanop@wakehealth.edu.

Funding

Laboratory Animal & Comparative Medicine TrainingT32OD010957 · OD · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI J. MARK CLINE · 2012 to 2026
$4.3M
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal OriginR01CA249087 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MILLER, LANCE DAVID, VOTANOPOULOS, KONSTANTINOS · 2021 to 2025
$2.5M
Establishing the Repertoire of Actionable Alterations in Appendiceal AdenocarcinomaR01CA258692 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Lance David Miller, Konstantinos Votanopoulos · 2022 to 2026
$2.5M
NCI NIH HHS R01 CA249087NCI NIH HHS R01 CA258692NIH HHS CA258692, CA249087, A158569NIH HHS T32 OD010957
6 · The paper itself

Abstract

Introduction Pheochromocytoma (PCC) and paraganglioma (PG) research is limited due to rarity of disease. We utilized patient-derived tumor organoids (PTOs) to explore personalized treatment options for these patients. Tumors were obtained from patients with PCC and PG who underwent operative resection and processed to biofabricate PTOs utilizing a collagen-based hydrogel. Blood was also obtained from patients to generate immune-enhanced PTOs (iPTOs). Organoids underwent treatment with chemotherapy, immunotherapy, or tyrosine kinase inhibitors. Cell viability was determined using multiple assays. Significant treatments demonstrated viability < 50% and p < 0.05 compared to controls. Twelve PCC and 4 PG tumors were obtained from December 2020 - May 2023. Viable PTOs were generated in 15/16 (93.8%) tumors for drug studies. Sunitinib (10 µM) demonstrated significant treatment efficacy in 9/14 PTOs (64.3%) with average post-treatment viability of 28%. A commonly utilized clinical regimen of cyclophosphamide, vincristine, doxorubicin and dacarbazine (10 µM) demonstrated significant treatment effect in 3/7 treated PTOs (42.9%) with average post-treatment viability of 25.5%. Only 1/13 iPTOs (7.7%) demonstrated sensitivity to Ipilimumab/Nivolumab. Cultured PTOs produced measurable norepinephrine on ELISA. PTOs are a feasible platform to study PCC and PG and their response to systemic treatments on a personalized level.

Indexed as

Adrenal Gland NeoplasmsDrug Screening Assays, AntitumorOrganoidsPheochromocytomaTissue EngineeringHumansPrecision MedicineTyrosine Kinase InhibitorsTyrosine Kinase InhibitorsOrganoidsParagangliomaPheochromocytomaPrecision oncologyTumor organoids

Identifiers

PMID41087622
PMCPMC12521660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.